Clinical Trials

Aeris is conducting a Phase 3 program evaluating the Biologic Lung Volume Reduction (BLVR) System.  The BLVR System is a minimally invasive treatment alternative for patients with advanced emphysema.  The treatment is designed to improve lung function and relieve symptoms for patients with emphysema. 

Ø       The BLVR treatment is administered using a Bronchoscope while under conscious sedation or anesthesia.

Ø       Patients will be admitted to the hospital for overnight observation following the BLVR procedure.

Ø       Patients will be under the care of a qualified doctor and will receive regular check-ups and health assessments throughout the study. 

Ø       Participants are divided into BLVR treatment and control groups at a ratio of 2:1 respectively.  Participants will not know to which group they have been assigned.  Upon completion of the follow-up period, participants assigned to the control group can be re-evaluated and if eligible, receive BLVR treatment.  

Further information regarding clinical studies sponsored by Aeris may be found at www.clinicaltrials.gov; enter “Aeris” in the “Search Clinical Trials” box.

Participation Criteria for Aeris BLVR Phase 3 Clinical Program

In order to participate in this clinical program, patients must have advanced upper lobe predominant emphysema that is disabling despite medical therapy and be able to tolerate bronchoscopy. 

In addition patients must have:

·          Stopped smoking

·          Not had previous major lung surgery

·          Not been diagnosed with clinically significant asthma, chronic bronchitis, or bronchiectasis

Participating Clinical Centers – Aeris BLVR Phase 3 Clinical Program

Approximately 45 clinical centers throughout the United States and Israel will be participating in this program.  Please check back regularly for an updated list of these participating centers.